학력
B.S., M.S. College of Pharmacy, Seoul National Univ.
Ph.D. Department of Pharmaceutical Sciences, University at Buffalo, SUNY, USA
주요경력
2001 – 2004 : Postdoctoral research fellow, Department of Clinical Pharmacology, Vanderbilt University Medical Center, USA
2004 – 2008 : Research Assistant Professor, Division of Hematology and Oncology, Vanderbilt University Medical Center, USA
2008 – 2014 : Assistant & Associate Professor, Department of Pharmaceutical Sciences Univ. of Kentucky, USA
2014 – present : Assistant & Associate Professor, College of Pharmacy, Seoul National University
주요관심 연구분야
- Pharmacokinetics/Pharmacodynamics/Pharmacometrics
- Molecular and genetic mechanisms for varying drug response
- Impact of drug transporters on drug therapy
- Evaluation of novel drug candidates and drug delivery systems for anticancer therapies
대표논문자료
- Chun S-E, Thakkar N, Park JE, Han S, Ryu G, Oh Y, Hahn H, Maeng SH, Lim Y-R, Han BW, Lee W. The N-terminal region of organic anion transporting polypeptide 1B3 (OATP1B3) plays an essential role in regulating its membrane trafficking. Biochem Pharmacol 131:98-105 (2017) (PMID: 28216016)
- Park J, Chun S-E, Reichel D, Min JS, Lee S-C, Han S, Ryoo G, Oh Y, Park S-H, Ryu H-M, Kim KB, Lee H-Y, Bae SK, Bae YB, Lee W. Polymer micelle formulation for the proteasome inhibitor drug carfilzomib: Anticancer efficacy and pharmacokinetic studies in mice. PLoS One 12(3):e0173247 (2017) (PMID: 28273121)
- Park J, Park JE, Hedrick VE, Wood KV, Bonham C, Lee W, Yeo Y. A comparative in vivo study of albumin-coated paclitaxel nanocrystals and abraxane. Small 23:e1703670 (2018) (PMID: 29570231, PMCID: PMC5908729).
- Gad S, Park J, Park JE, Fetih G, Tous S, Lee W, Yeo Y. Enhancing docetaxel delivery to multidrug-resistant cancer cells with albumin-coated nanocrystals. Mol Pharm 13:871-881 (2018) (PMID 29341617)
- Oh Y, Jeong Y-S, Kim M-S, Min JS, Ryoo G, Park JE, Jun Y, Song Y-K, Chun S-E, Han S, Bae SK, Chung S-J, Lee W. Inhibition of organic anion transporting polypeptide 1B1 and 1B3 by betulinic acid: Effects of pre-incubation and albumin in the media. J Pharm Sci 107:1713-1723 (2018) (PMID 29462635)
- Lee MJ, Miller Z, Park JE, Bhattarai D, Lee W, Kim KB. H727 cells are inherently resistant to the proteasome inhibitor carfilzomib, yet require proteasome activity for cell survival and growth. Sci Rep 9(1):4089 (2019)
- Park JE, Park J, Jun Y, Oh Y, Ryoo G, Jeong Y, Gadalla HH, Min JS, Jo JH, Song MG, Kang KW, Bae SK, Yeo Y, Lee W. Expanding therapeutic utility of carfilzomib for breast cancer therapy by novel albumin-coated nanocrystal formulation. J Controlled Rel 302:148-159 (2019) (PMID: 30954620)
- Lee MJ, Bhattarai D, Yoo ZS, Miller Z, Park JE, Lee W, Driscoll J, Kim KB. Development of novel epoxyketone-based proteasome inhibitors as a strategy to overcome cancer resistance to carfilzomib and bortezomib. J Med Chem 62(9):4444-4455 (2019) (PMID: 30964987)
- Asaumi R, Menzel K, Lee W, Nunoya K, Imawaka H, Hiroyuki K, Sugiyama Y. Expanded PBPK Model of Rifampicin for Predicting Interactions with Drugs and an Endogenous Biomarker via Complex Mechanisms including OATP1B Induction CPT: Pharmacometrics Syst Pharmacol (2019, in press) (PMID: 31420941)
For more information,
http://orcid.org/0000-0001-7805-869X
https://openwetware.org/wiki/Lee:Publications
